Zacks Research Analysts Raise Earnings Estimates for Amgen Inc. (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) – Investment analysts at Zacks Research raised their Q2 2025 earnings estimates for shares of Amgen in a research report issued on Tuesday, August 27th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings per share of $5.11 for the quarter, up from their previous estimate of $5.05. The consensus estimate for Amgen’s current full-year earnings is $19.50 per share. Zacks Research also issued estimates for Amgen’s FY2025 earnings at $20.52 EPS.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a net margin of 12.74% and a return on equity of 156.21%. The firm had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. During the same quarter last year, the business posted $5.00 earnings per share. The company’s revenue for the quarter was up 20.1% on a year-over-year basis.

Other equities research analysts also recently issued reports about the stock. BMO Capital Markets raised their price objective on shares of Amgen from $336.00 to $355.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Royal Bank of Canada raised their price objective on shares of Amgen from $332.00 to $362.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 7th. TD Cowen raised their price objective on shares of Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Barclays upgraded shares of Amgen from an “underweight” rating to an “equal weight” rating and raised their price objective for the stock from $230.00 to $300.00 in a research report on Friday, May 3rd. Finally, William Blair upgraded shares of Amgen from a “market perform” rating to an “outperform” rating in a research report on Friday, May 3rd. Eleven investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $326.89.

Amgen Trading Up 0.9 %

Shares of NASDAQ:AMGN opened at $333.83 on Friday. The company has a 50-day simple moving average of $324.48 and a 200 day simple moving average of $300.43. The company has a debt-to-equity ratio of 11.96, a quick ratio of 0.98 and a current ratio of 1.42. The company has a market capitalization of $179.08 billion, a P/E ratio of 47.69, a price-to-earnings-growth ratio of 2.78 and a beta of 0.58. Amgen has a 52-week low of $248.38 and a 52-week high of $346.85.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were paid a dividend of $2.25 per share. The ex-dividend date of this dividend was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 2.70%. Amgen’s payout ratio is presently 128.57%.

Institutional Trading of Amgen

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Keynote Financial Services LLC grew its stake in shares of Amgen by 0.6% during the second quarter. Keynote Financial Services LLC now owns 4,898 shares of the medical research company’s stock worth $1,530,000 after buying an additional 30 shares during the last quarter. Ascent Group LLC grew its stake in shares of Amgen by 0.3% during the second quarter. Ascent Group LLC now owns 10,949 shares of the medical research company’s stock worth $3,421,000 after buying an additional 31 shares during the last quarter. RFP Financial Group LLC grew its stake in shares of Amgen by 17.1% during the first quarter. RFP Financial Group LLC now owns 219 shares of the medical research company’s stock worth $62,000 after buying an additional 32 shares during the last quarter. Hofer & Associates. Inc grew its stake in shares of Amgen by 0.5% during the second quarter. Hofer & Associates. Inc now owns 6,477 shares of the medical research company’s stock worth $2,024,000 after buying an additional 32 shares during the last quarter. Finally, Blossom Wealth Management grew its stake in shares of Amgen by 3.3% during the second quarter. Blossom Wealth Management now owns 1,023 shares of the medical research company’s stock worth $320,000 after buying an additional 33 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.